In life, we must know how to move with the times. After all, such a skill helps us extensively around pursuing sustainable growth. Now, when you have the said luxury at your disposal, you are also likely to see some really interesting by-products emerge from it on a rather consistent basis, and yet a quick assessment will reveal that none of them really stack up with what technology has done so far. Ever since turning up on the scene, technology has enjoyed a rather unique stature among people. In fact, the dynamic has only become more and more unprecedented with every new permutation of the concept. While looking through these permutations, one might observe the way in which technology has managed to impact the entire spectrum without losing its footing for even a second. However, the ridiculous achievement takes up a different significance altogether once you realize how the creation has literally transformed an integral area like healthcare. The healthcare and technology link-up, as dubious as it sounded at first, has actually went on to scale up medical care beyond all our predictions. Despite having already done a ton, it is still delivering the goods, and that was backed up well by Eli Lily’s recent announcement.
Eli Lily has officially revealed plans to dedicate over $1 billion towards the construction of a new manufacturing site in Concord, North Carolina. Expected to drastically increase company’s manufacturing prowess and create nearly 600 jobs, the new site will be used to produce parenteral products and devices. Interestingly enough, Lily picked Concord because of its close proximity with universities, which boast a specialization in STEM (science, technology, engineering, and math) discipline. Apart from that, the city’s transportation infrastructure also reportedly played a huge role in the final decision. Nevertheless, it’s not the first time Lily has deemed North Carolina as the perfect base for company’s investment. In 2020, the pharmaceutical giant forked out $470 million to build a research triangle park in the state.
“Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world,” said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. “Expanding our manufacturing footprint in North Carolina enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow.”
Even though Lily has invested quite heavily in global manufacturing over the last five years, it is still convinced about making more of these moves. As far as future is concerned, the company’s goal is to deliver new medicines for many life-altering conditions such as cancer, diabetes, Alzheimer’s disease, and autoimmune disorders.
